Getinge AB (publ)
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mattias Perjos
- Full Time Employees
- 11,827
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Lindholmspiren 7A Gothenburg Sweden 417 56
- IPO Date
- Aug 17, 2012
- Website
- getinge.com
- Similar Companies
- Business
- Getinge AB (publ) develops and markets medical devices and therapy systems for operating rooms, intensive care units, and life science institutions worldwide. The company offers products and solutions across three primary business areas including Acute Care Therapies with ventilators, extracorporeal membrane oxygenation systems, intra-aortic balloon pumps, and heart-lung machines; Surgical Workflows encompassing operating tables, surgical lights, sterile reprocessing equipment such as washers, sterilizers like Poladus 150 low-temperature sterilizers, and drying cabinets; and Life Science featuring washers such as GEW 888 neo, single-use assemblies, sterile transfer bags like DPTE-BetaBag, and bioprocess development tools; complemented by digital health software including Talis clinical decision support and Advanta V12 covered stent systems. Getinge AB (publ), founded in 1904 and headquartered in Gothenburg, Sweden, employs approximately 12,000 people and operates in 40 countries with a global presence serving healthcare providers, hospitals, ambulatory surgery centers, pharmaceutical production, and research laboratories. Recent developments include the completion of the acquisition of Paragonix Technologies in September 2024 for approximately USD 253 million upfront to enhance organ preservation offerings in transplant markets; new product launches in 2024 such as Poladus 150 sterilizer, Talis software with 510(k) clearance, Advanta V12 EU MDR approval, GEW 888 neo washer, and renewable-source DPTE-BetaBag; the regaining of CE Mark for intra-aortic balloon pump Cardiosave in 2025 enabling resumed deliveries; and earlier acquisition of High Purity New England in 2023 to expand biopharma single-use assemblies.
Getinge AB (publ) (GNGBY) Q1 2026 Earnings Call Transcript
Analyzing Danaher (NYSE:DHR) and Getinge (OTCMKTS:GNGBY)
Getinge AB (publ) (GNGBY) Q4 2025 Earnings Call Transcript
Contrasting AMN Healthcare Services (NYSE:AMN) & Getinge (OTCMKTS:GNGBY)
Reviewing Getinge (OTCMKTS:GNGBY) & Pediatrix Medical Group (NYSE:MD)
Getinge AB (publ) (GNGBY) Q3 2025 Earnings Call Transcript
Getinge AB (publ) (GNGBF) Q2 2025 Earnings Call Transcript
Getinge AB (publ) (GNGBF) Q1 2025 Earnings Call Transcript
Getinge AB (GNGBF) Q4 2024 Earnings Call Transcript
Getinge AB (GNGBF) Q3 2024 Earnings Call Transcript
Getinge misses Q3 forecasts, weighed by quality and delivery issues
Getinge AB (GNGBF) Q2 2024 Earnings Call Transcript
Getinge AB (GNGBF) Q1 2024 Earnings Call Transcript
Getinge AB (publ) (GNGBF) Q3 2023 Earnings Call Transcript
Getinge: Turnaround Catalysts To Outperform Healthcare Peers
Getinge AB (publ) (GNGBF) Q2 2023 Earnings Call Transcript
Getinge AB (publ) (GNGBF) Q4 2022 Earnings Call Transcript
Getinge AB (GNGBF) CEO Mattias Perjos on Q2 2022 Results - Earnings Call Transcript
Getinge AB (GNGBF) CEO Mattias Perjos on Q1 2022 Results - Earnings Call Transcript
Getinge AB's (GNGBF) CEO Mattias Perjos on Q3 2021 Results - Earnings Call Transcript